Summary Slides - HCT Trends and Survival Data
Using information from our outcomes database, CIBMTR periodically prepares and distributes charts summarizing current uses and outcomes of allogeneic and autologous hematopoietic cell transplantation (HCT) in a set of Summary Slides.
Summary Slides - Part I
Summary Slides - Part II
Request Summary Slides
Supplemental information on Summary Slides
To cite Summary Slides
Summary Slides – Part I
Part I focuses on trends in the use of HCT according to donor type, graft sources, patient age and transplant regimens. Early outcomes such as mortality rates at day 100 post HCT and causes of death are also included in this series.
Access:
- Web presentation (best viewed in Internet Explorer)
- CIBMTR Newsletter (PDF) – August 2009
Summary Slides – Part II
Part II focuses on survival outcomes by age, disease, transplant and donor type, and by conditioning regimen intensities.
Access:
- Web presentation (best viewed in Internet Explorer)
- CIBMTR Newsletter (PDF) – December 2009
Request Summary Slides
Slides are available upon request by contacting:
Tanya Pedersen
CIBMTR
3001 Broadway St. N.E.
Suite 110
Minneapolis, MN 55413-1753 USA
Telephone: 612-884-8607
Fax: 612-884-8661
E-mail: info-request@mcw.edu
Supplemental information on Summary Slides
- Charts with total transplant numbers are estimates based on data reported to CIBMTR, adjusted according to transplant type. These adjustments come from comparisons with other national and international databases.
- Acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML) are classified as:
- early phase (first complete remission [CR1] or first chronic phase [CP1]),
- intermediate phase (second or subsequent CR or CP or accelerated phase [AP]), or
- advanced phase (primary induction failure, active disease or blastic phase) disease.
- Myelodysplastic syndrome (MDS) is divided into:
- early (refractory anemia [RA] or refractory anemia with ringed sideroblasts [RARS]), and
- advanced (refractory anemia with excess blasts [RAEB] or chronic myelomonocytic leukemia [CMML]) disease.
- Lymphoma is classified according to sensitivity to prior chemotherapy (chemosensitive or chemoresistant).
- The classification of conditioning regimen intensities is based on the agents, doses and schedules used. Several classifications are available, and for this report we used a composite classification. Cases defined as reduced-intensity by the transplant center were classified as reported. Cases without such information and with available data on chemotherapy agents, radiation and doses, were classified according to the CIBMTR operational definition of conditioning regimen intensity:
- Myeloablative conditioning regimen: regimens with total body irradiation single doses of ≥500 cGy, or fractionated doses totalling ≥800 cGy, busulfan doses of >9mg/kg, or melphalan doses of >150 mg/m2 given either as single agents or in combination with other drugs.
- Reduced-intensity conditioning regimen: regimens with lower doses of total body irradiation, fractionated radiation therapy, busulfan, and melphalan than those used to define a myeloablative conditioning regimen (above).
To cite Summary Slides
CIBMTR Summary Slides - Part I:
Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: Part I - CIBMTR Summary Slides, 2009. CIBMTR Newsletter [serial online], 2009; 15(1):7-11.
CIBMTR Summary Slides Part II:
Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: Part II - CIBMTR Summary Slides, 2009. CIBMTR Newsletter [serial online], 2009; 15(2):7-11.
To view PDF documents you will need Adobe Reader.
